Physiologically-based pharmacokinetic model for evaluating gender-specific exposures of N-nitrosodimethylamine (NDMA)

被引:3
|
作者
Kang, Dong Wook [1 ]
Kim, Ju Hee [1 ]
Choi, Go-Wun [1 ]
Cho, Seok-jin [1 ]
Cho, Hea-Young [1 ]
机构
[1] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea
关键词
N-nitrosodimethylamine (NDMA); Physiologically-based pharmacokinetic (PBPK) model; Toxicokinetics; Tissue distribution; Monte Carlo simulation; CHRONIC INGESTION; INBRED RATS; LIVER; NITROSODIETHYLAMINE; METABOLISM; DIMETHYLNITROSAMINE; CARCINOGENESIS; MICE; AGE;
D O I
10.1007/s00204-023-03652-8
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
N-nitrosodimethylamine (NDMA) is classified as a human carcinogen and could be produced by both natural and industrial processes. Although its toxicity and histopathology have been well-studied in animal species, there is insufficient data on the blood and tissue exposures that can be correlated with the toxicity of NDMA. The purpose of this study was to evaluate gender-specific pharmacokinetics/toxicokinetics (PKs/TKs), tissue distribution, and excretion after the oral administration of three different doses of NDMA in rats using a physiologically-based pharmacokinetic (PBPK) model. The major target tissues for developing the PBPK model and evaluating dose metrics of NDMA included blood, gastrointestinal (GI) tract, liver, kidney, lung, heart, and brain. The predictive performance of the model was validated using sensitivity analysis, (average) fold error, and visual inspection of observations versus predictions. Then, a Monte Carlo simulation was performed to describe the magnitudes of inter-individual variability and uncertainty of the single model predictions. The developed PBPK model was applied for the exposure simulation of daily oral NDMA to estimate blood concentration ranges affecting health effects following acute-duration (<= 14 days), intermediate-duration (15-364 days), and chronic-duration (>= 365 days) intakes. The results of the study could be used as a scientific basis for interpreting the correlation between in vivo exposures and toxicological effects of NDMA.
引用
收藏
页码:821 / 835
页数:15
相关论文
共 50 条
  • [31] Degradation of Amine-Based Water Treatment Polymers during Chloramination as N-Nitrosodimethylamine (NDMA) Precursors
    Park, Sang-Hyuck
    Wei, Shuting
    Mizaikoff, Boris
    Taylor, Amelia E.
    Favero, Cedrick
    Huang, Ching-Hua
    ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2009, 43 (05) : 1360 - 1366
  • [32] Bio-reduction of N-nitrosodimethylamine (NDMA) using a hydrogen-based membrane biofilm reactor
    Chung, Jinwook
    Ahn, Chang-Hoon
    Chen, Zhuo
    Rittmann, Bruce E.
    CHEMOSPHERE, 2008, 70 (03) : 516 - 520
  • [33] Mechanistic insight for the N-nitrosodimethylamine (NDMA) formation potential of amine-based water treatment polymers
    Park, Sang-Hyuck
    Wei, Shuting
    Mizaikoff, Boris
    Taylor, Amelia E.
    Aral, Mustafa
    Huang, Ching-Hua
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 427 - 427
  • [34] PREDICTION OF ANTICHOLINESTERASE ACTIVITY AND URINARY METABOLITES OF ISOFENPHOS - USE OF A PERCUTANEOUS PHYSIOLOGICALLY-BASED PHARMACOKINETIC PHYSIOLOGICALLY-BASED PHARMACODYNAMIC MODEL
    KNAAK, JB
    ALBAYATI, MA
    RAABE, OG
    BLANCATO, JN
    BIOMARKERS OF HUMAN EXPOSURE TO PESTICIDES, 1994, 542 : 284 - 300
  • [35] Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data
    Hornik, Christoph P.
    Wu, Huali
    Edginton, Andrea N.
    Watt, Kevin
    Cohen-Wolkowiez, Michael
    Gonzalez, Daniel
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1343 - 1353
  • [36] Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction
    Lu, Jingtao
    Goldsmith, Michael-Rock
    Grulke, Christopher M.
    Chang, Daniel T.
    Brooks, Raina D.
    Leonard, Jeremy A.
    Phillips, Martin B.
    Hypes, Ethan D.
    Fair, Matthew J.
    Tornero-Velez, Rogelio
    Johnson, Jeffre
    Dary, Curtis C.
    Tan, Yu-Mei
    PLOS COMPUTATIONAL BIOLOGY, 2016, 12 (02)
  • [37] A Δ9-Tetrahydrocannabinol Physiologically-Based Pharmacokinetic Model Development in Humans
    Methaneethorn, Janthima
    Poomsaidorn, Chomkanang
    Naosang, Kanyamas
    Kaewworasut, Parichart
    Lohitnavy, Manupat
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (04) : 495 - 511
  • [38] Physiologically-based pharmacokinetic model for pregnancy as a tool for investigation of developmental mechanisms
    Young, JF
    COMPUTERS IN BIOLOGY AND MEDICINE, 1998, 28 (04) : 359 - 364
  • [39] Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans
    Jagdale, Prabhas
    Sepp, Armin
    Shah, Dhaval K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (06) : 607 - 624
  • [40] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL TO SUPPORT OPHTHALMIC SUSPENSIONS DEVELOPMENT.
    Le Merdy, M.
    Fan, J.
    Babiskin, A. H.
    Zhao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S7 - S7